Theranostics Market Size, Growth and Trends with Key Players

Market Size

◉2024 → USD 2.42 Billion (baseline market value).

◉2025 → USD 2.8 Billion (early expansion, fueled by PET/SPECT adoption).

◉2034 (Projection) → USD 10.21 Billion.

Growth Rate

◉(2025–2034) → CAGR 15.46%, among the fastest in precision oncology markets.

Regional Contribution (2024):

◉North America → 40% share, advanced healthcare + nuclear medicine infrastructure.

◉Asia Pacific → fastest growth forecast (oncology adoption, new radiopharmaceuticals).

◉Europe → driven by supportive policies, R&D, biotech collaborations.

Market Trends

◉Oncology-Centric Growth → Prostate and neuroendocrine cancers dominate adoption, with PSMA-based tracers and Lu-177 DOTATATE therapy.

◉Shift to Non-Oncology Applications → Expansion into neurology, cardiology, and infectious diseases (e.g., radiopharmaceuticals for brain disorders).

◉AI in Imaging → AI integration in PET/SPECT and radiomics is enabling more precise tumor mapping.

◉Nanoparticle-Based Therapies → Use of liposomes, polymeric nanoparticles, and gold nanoparticles to enhance targeted drug delivery.

◉Growing Radiopharmaceutical Investments → Partnerships like NorthStar + YAP (2025) and Curium +

◉PDRadiopharma (2024) expanding clinical use.

◉Collaborative Ecosystem → Industry-academic collaborations (Siemens Healthineers + MGH, 2025) accelerating adoption.

◉Personalized Medicine Push → Increased demand for companion diagnostics supporting therapy selection.

◉AI-driven Trial Accessibility → SNMMI’s AI-based Global Radiopharmaceutical Trial Finder (2025) enhancing patient-trial matching.

◉Infrastructure Barriers → High expenditure for PET/SPECT systems and isotope production facilities restrains widespread adoption.

AI’s Role in Theranostics

AI in Radiomics

◉Enables quantitative tumor analysis from PET/SPECT/CT scans.

◉Helps detect heterogeneity in tumors → better selection of targeted therapy.

AI in Therapy Optimization

◉Optimizes radiation dose planning → minimizes exposure to healthy tissues.

◉Example: AI-based anatomical + tumor property analysis improving radiation safety.

AI in Clinical Trial Matching

◉SNMMI’s Global Radiopharmaceutical Trial Finder (2025) → AI-driven platform matching patients with theranostic clinical trials globally.

AI in Predictive Modeling

◉Predicts treatment response curves for individual patients.

◉Integration with biomarkers → precision dosing recommendations.

AI in Drug Discovery & Development

◉Helps in identifying new molecular targets (e.g., HER2, FAP).

◉Speeds up preclinical testing by simulating molecular interactions.

AI in Imaging Centers

◉Diagnostic imaging centers adopting AI for automated scan analysis → faster and cheaper than manual radiologist evaluations.

Regional Insights

1. North America (40% Market Share, 2024)

◉Cancer prevalence (prostate, NETs) driving PSMA-targeted radiopharmaceuticals.

◉Robust regulatory & reimbursement framework supporting adoption.

◉Key collaboration (Jan 2025) → NorthStar Medical Radioisotopes + YAP Therapeutics to develop novel radiopharmaceuticals.

2. Asia Pacific (Fastest Growth, 2025–2034)

◉China: Government’s Medical Isotopes Development Plan (2021–2035) expanding nuclear medicine capacity.

◉Japan: Investments in PET/CT imaging + theranostic radiotracers; collaboration with Curium for PSMA-based therapies.

◉India & South Korea: Expanding PET/SPECT infrastructure, rising cancer burden.

3. Europe

◉Germany: Strong biotech ecosystem; Nuclidium raised CHF 79M (2025) for copper-based radiopharma pipeline.

◉UK: Growing awareness, partnerships (Lemer Pax + Synapse Medical, 2025) to expand radiation protection systems.

◉France, Italy, Spain → National nuclear medicine programs fueling adoption.

4. Latin America

◉Brazil: ICPO + SBMN partnership (2025) to establish Clinical Theranostics Centers.

◉Growing use of PET/SPECT but limited isotope production infrastructure.

5. Middle East & Africa (MEA)

◉Saudi Arabia, UAE → rapid investments in advanced imaging infrastructure.

◉South Africa → limited adoption but growing nuclear medicine R&D centers.

Top Companies (In-Depth: product, overview, core strengths)

GE HealthCare

◉Products: PET/CT, SPECT/CT, CT systems, radiopharmacy automation.

◉Overview: Leader in diagnostic hardware & imaging workflow software; broad clinical installed base.

◉Strength: Global distribution, upgrade pipelines, strong clinical evidence and service footprint enabling hospital adoption.

Siemens Healthineers AG

◉Products: PET, PET/CT, advanced imaging analytics, AI-enabled imaging suites; therapy informatics via research collaborations.

◉Overview: Heavy investment in imaging + digital platforms; active research partnerships (e.g., MGH Therapy Command Center).

◉Strength: Deep clinical partnerships, end-to-end imaging solutions and growing therapy orchestration capabilities.

Thermo Fisher Scientific Inc.

◉Products: Radiochemistry consumables, lab analyzers, clinical diagnostics, radiopharma manufacturing tools.

◉Overview: Strong in upstream lab and manufacturing supply for radiopharma development.

◉Strength: Global CDMO-like capabilities, regulatory and quality expertise for cGMP radiochemistry.

Telix Pharmaceuticals Limited

◉Products: PSMA and other prostate cancer imaging/therapeutic radiopharmaceuticals (Gozellix launch).

◉Overview: Focused oncology theranostics player with diagnostic and therapeutic pipeline.

◉Strength: Clinical focus, regulatory progress in targeted prostate imaging and therapy markets.

Curium Pharma

◉Products: Broad nuclear medicine portfolio, including Lu-177 products and isotope manufacturing.

◉Overview: Large nuclear medicine player with manufacturing reach in APAC and Europe.

◉Strength: Radiopharma manufacturing scale, regulatory filings and commercial partnerships (e.g., Japan collaborations).

NorthStar Medical Radioisotopes / Others (e.g., Bracco, Bayer, Novartis)

◉Overview: Mix of isotope producers (NorthStar), imaging/contrast firms (Bracco), big-pharma R&D (Novartis/Bayer) now entering theranostics through acquisitions, licensing and internal pipelines.

◉Strengths: Vertical integration potential (drug + diagnostic + supply), brand/regulatory capital, and payer relationships.

Market Dynamics (In-Depth)

Drivers

Clinical need & epidemiology

◉Rising cancer prevalence (US, China, India, Japan) and demand for personalized oncology drive adoption of imaging + targeted therapy pairs.

Technological innovation

◉Molecular imaging advances (new PET tracers, FAPI, PSMA), nanoparticle formulations, and AI analytics accelerate diagnostic sensitivity and therapy selection.

Commercial enablers

◉CDMO expansion, oncology trial activity, and increasing hospital-level theranostics programs (centers of excellence) lower commercialization barriers.

Restraints

Infrastructure & capital intensity

◉High upfront costs for scanners, cyclotrons/generators and shielded radiopharmacies; training and staffing shortages.

Supply chain fragility

◉Short isotope half-lives require local/regional production; limited global reactor/cyclotron capacity constrains scale (logistics and shelf-life issues).

Regulatory & reimbursement complexity

◉Novel agents combine drug and radioactive material regulations; inconsistent guidance across regions slows global launches.

Opportunities

Non-oncology expansion

◉Neurology, cardiology, and infectious disease theranostics present new addressable markets beyond oncology.

AI & precision dosing

◉AI-driven dosimetry and outcome prediction can increase therapeutic efficacy and improve payer acceptance through better value demonstration.

Biomarker discovery & companion diagnostics

◉New molecular targets (HER2, FAP, CXCR4) and biomarker-guided patient selection increase therapy success rates.